Carmen Bozic Sells Shares of Vertex Pharmaceuticals
Vertex's EVP and CMO Carmen Bozic sold 1,020 shares on June 18, 2026, as part of a planned transaction.
Key Points
- Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals, sold 1,020 shares at an average price of $462.17 on June 18, 2026.
- Vertex Pharmaceuticals has a market cap of approximately $118.5 billion and a P/E ratio of 27.7, with shares trading near $466.79 on Wednesday.
- Analysts maintain a positive outlook on Vertex, with a consensus rating of 'buy' and a mean price target of $548.69.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 18, 2026, Carmen Bozic, Executive Vice President and Chief Medical Officer of Vertex Pharmaceuticals Incorporated, sold 1,020 shares of the company. The shares were sold at an average price of $462.17, amounting to a total transaction value of $471,413. This sale was conducted as part of a pre-arranged trading plan.
Insider Buying and Selling at Vertex Pharmaceuticals Incorporated
Carmen Bozic has been active in selling Vertex Pharmaceuticals shares recently. On June 15, she sold 4,062 shares at $450 each, and on June 5, she sold another 1,745 shares at the same price. Additionally, other executives like Joy Liu, EVP and Chief Legal Officer, sold 828 shares at $439.91 on June 1, 2026.
Vertex Pharmaceuticals Incorporated Stock Down 13.8%
Shares of NasdaqGS:VRTX traded near $466.79 on Wednesday. Vertex Pharmaceuticals, a biotechnology firm based in Boston, has a market cap of approximately $118.5 billion. The company has a P/E ratio of 27.7 and a forward P/E of 21.7. Its stock has ranged from a low of $362.50 to a high of $507.92 over the past 52 weeks. The company maintains a strong financial position with a current ratio of 3.02 and a quick ratio of 2.38.
$VRTX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On May 6, 2026, Barclays maintained its 'buy' rating for Vertex Pharmaceuticals with a price target of $615. Similarly, Morgan Stanley and Bernstein both maintained 'buy' ratings on May 5, with targets of $616 and $572, respectively. The consensus among analysts is a 'buy' recommendation, with a mean price target of $548.69 based on 29 analyst opinions.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a biotechnology company headquartered in Boston, Massachusetts. It focuses on developing transformative medicines for serious diseases, particularly in specialty markets like cystic fibrosis, sickle cell disease, and beta thalassemia. Vertex's flagship products include TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for cystic fibrosis, among others. The company is led by CEO Dr. Reshma Kewalramani and employs approximately 6,400 people.
Bottom Line
Carmen Bozic's planned sale of Vertex Pharmaceuticals shares is part of a series of insider transactions, reflecting routine portfolio management. Vertex remains a significant player in the biotechnology sector, with strong financials and a positive analyst outlook. Investors often keep an eye on such insider activities as part of their broader investment strategy.
Get Vertex Pharmaceuticals Incorporated alerts
New 13F filings, insider trades, and analyst moves on $VRTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.